Oncorus Inc. has closed a $79.5m series B round to initiate the first clinical trial for its herpes simplex-based oncolytic virus technology platform and select the first product candidate for its other platform using a synthetic virus for intravenous, systemic administration that enables repeat dosing in early 2020, the firm announced 21 August.
Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
